U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

Tampa General Hospital is once again ranked as the #1 hospital in Tampa Bay by U.S. News & World Report for 2021-2022.

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay’s top hospital. Tampa General is also listed among the top four hospitals in Florida and ranked as one of the nation’s top 50 hospitals in five medical specialties, according to the digital media company.

The annual Best Hospitals rankings and ratings, now in their 32nd year, are designed to help patients and their doctors in making informed decisions about where to receive care for challenging health conditions or for common elective procedures. The high U.S. News rankings are a sign of Tampa General’s ability to treat the most complex illnesses and conditions, said TGH President and CEO John Couris.

“Year after year, Tampa General has been recognized as a leading healthcare system by U.S. News & World Report, considered by healthcare consumers as the global leader in quality rankings. Consistency in performance is what is most important as we continue on our journey to become the safest and most innovative academic health system in America,” Couris said. “I’m incredibly proud of our physicians and team members who deliver world-class care to our patients every day. Their dedication and commitment is the reason that Tampa General ranks so highly.”

Tampa General, the primary teaching hospital of the USF Health Morsani College of Medicine and one of the nation’s largest hospitals, is the leading academic medical center on the West Coast of Florida. It is known for performing the most challenging procedures and treating the most complex illnesses.

Tampa General is ranked as one of the nation’s 50 top hospitals, as well as the top hospital in Florida, in these five medical specialties:

  • Ear, Nose & Throat – ranked #21 in U.S. and #1 in Florida
  • Orthopedics – ranked #23 in U.S. and #1 in Florida
  • Gastroenterology & GI Surgery – ranked #26 in U.S. and tied for #1 in Florida
  • Diabetes & Endocrinology – ranked #28 in U.S. and #1 in Florida
  • Rehabilitation – ranked #36 in U.S. and tied for #1 in Florida

Tampa General also ranks as “high performing,” or among the top 10% of U.S. hospitals, in four more specialties:

  • Cancer
  • Geriatrics
  •  Neurology & Neurosurgery
  • Pulmonology & Lung Surgery

Finally, Tampa General also ranks as “high performing” in 12 procedures and conditions that include: Abdominal Aortic Aneurysm Repair, Acute Kidney Failure, COPD, Diabetes, Heart Attack, Heart Bypass Surgery, Heart Failure, Hip Replacement, Knee Replacement, Pneumonia, Spinal Fusion and Stroke.

For the 2021-22 rankings and ratings, U.S. News evaluated more than 4,750 medical centers nationwide in 15 specialties and 17 procedures and conditions. In the 15 specialty areas, 175 hospitals were ranked in at least one specialty. In rankings by state and metro area, U.S. News recognized hospitals as “high performing” across multiple areas of care.

“This year’s expanded report from U.S. News includes new ratings for important procedures and conditions to help each patient pick the right hospital for the type of care they need,” said Ben Harder, managing editor and chief of health analysis at U.S. News. “Hospitals faced incredible challenges this past year, and the best of them have provided great care throughout the pandemic and continue to offer excellent care today.”

The U.S. News Best Hospitals methodologies in most areas of care are based largely on objective measures such as risk-adjusted survival and discharge-to-home rates, volume, and quality of nursing, among other care-related indicators. Best Hospitals was produced by U.S. News with RTI International, a leading research organization based in Research Triangle Park, N.C.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version